{"id":"centhaquine-standard-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Increased liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Centhaquine binds to sphingosine-1-phosphate (S1P) receptors, particularly S1P1, which enhances endothelial barrier function, reduces vascular permeability, and improves tissue perfusion. By stabilizing the microvasculature and reducing inflammatory cell infiltration, it mitigates organ damage in septic and hemorrhagic shock when combined with standard supportive care.","oneSentence":"Centhaquine is a first-in-class small molecule that activates sphingosine-1-phosphate receptors to improve microcirculation and reduce cellular injury in shock states.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:49.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Septic shock (in combination with standard treatment)"},{"name":"Hemorrhagic shock (in combination with standard treatment)"}]},"trialDetails":[{"nctId":"NCT05956418","phase":"PHASE4","title":"A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients","status":"RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2021-08-13","conditions":"Hypovolemic Shock","enrollment":400},{"nctId":"NCT05251181","phase":"PHASE3","title":"A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent","status":"NOT_YET_RECRUITING","sponsor":"Pharmazz, Inc.","startDate":"2026-02","conditions":"Hypovolemic Shock","enrollment":430},{"nctId":"NCT04045327","phase":"PHASE3","title":"Efficacy of PMZ-2010 (Centhaquine) a Resuscitative Agent for Hypovolemic Shock","status":"COMPLETED","sponsor":"Pharmazz, Inc.","startDate":"2019-01-31","conditions":"Hypovolemic Shock","enrollment":105},{"nctId":"NCT04056065","phase":"PHASE2","title":"PMZ-2010 (Centhaquine) as a Resuscitative Agent for Hypovolemic Shock","status":"COMPLETED","sponsor":"Pharmazz, Inc.","startDate":"2017-05-29","conditions":"Hypovolemic Shock, Blood Loss","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PMZ-2010"],"phase":"phase_3","status":"active","brandName":"Centhaquine + Standard Treatment","genericName":"Centhaquine + Standard Treatment","companyName":"Pharmazz, Inc.","companyId":"pharmazz-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Centhaquine is a first-in-class small molecule that activates sphingosine-1-phosphate receptors to improve microcirculation and reduce cellular injury in shock states. Used for Septic shock (in combination with standard treatment), Hemorrhagic shock (in combination with standard treatment).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}